COMPASS Pathways (CMPS) to Release Earnings on Thursday

Key Points

• COMPASS Pathways is set to release its Q3 2025 earnings on October 30th, with analysts expecting a loss of ($0.40) per share.
• The company's stock has declined by 2.5%, currently trading at $6.34, with a market capitalization of $608.26 million.
• Institutional investors own 46.19% of COMPASS Pathways' stock, with several firms increasing their positions significantly in the second quarter.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect COMPASS Pathways to post earnings of ($0.40) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

COMPASS Pathways Stock Down 2.5%

NASDAQ:CMPS opened at $6.34 on Thursday. The firm has a market capitalization of $608.26 million, a price-to-earnings ratio of -3.45 and a beta of 2.21. COMPASS Pathways has a twelve month low of $2.25 and a twelve month high of $7.09. The stock's 50 day moving average price is $5.38 and its two-hundred day moving average price is $4.40. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Exome Asset Management LLC acquired a new position in COMPASS Pathways in the 2nd quarter valued at about $598,000. Northeast Financial Consultants Inc acquired a new position in shares of COMPASS Pathways in the second quarter valued at approximately $59,000. Balyasny Asset Management L.P. grew its position in shares of COMPASS Pathways by 38.0% in the second quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company's stock valued at $2,394,000 after purchasing an additional 235,345 shares during the last quarter. Nantahala Capital Management LLC grew its position in shares of COMPASS Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company's stock valued at $11,704,000 after purchasing an additional 1,350,698 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of COMPASS Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company's stock valued at $686,000 after purchasing an additional 71,112 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on CMPS shares. Canaccord Genuity Group restated a "buy" rating and set a $15.00 target price on shares of COMPASS Pathways in a report on Friday, August 1st. HC Wainwright lowered their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, August 4th. BTIG Research boosted their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a "buy" rating in a research note on Monday, October 13th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.